Tekmira Pharmaceuticals Corporation's Lipid Nanoparticle (LNP) Technology Highlighted in Two Peer-Reviewed Scientific Publications

Published: Aug 30, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

VANCOUVER, British Columbia, Aug. 30, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced the publication of two articles in peer-reviewed scientific journals – the Journal of Infectious Diseases and New England Journal of Medicine – that highlight results enabled by Tekmira's lipid nanoparticle (LNP) technology.

Help employers find you! Check out all the jobs and post your resume.

Back to news